Has Pejman Cohan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,156,041 in general payments to Pejman Cohan, MD across 685 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pejman Cohan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pejman Cohan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pejman Cohan, MD

Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1225064884

Payments from drug & device makers

$2,156,041in general payments, 2019–2025

Across 685 payments — averaging $3147.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Corcept Therapeutics$2.1M
Ascendis Pharma Endocrinology Inc$34K
Chiasma, Inc.$26K
Amgen$15K
Amryt Pharma Holdings Ltd$4K
Antares Pharma, Inc.$4K
plus $12K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Corcept Therapeutics	31	$2,060,435
Ascendis Pharma Endocrinology Inc	110	$34,135
Chiasma, Inc.	6	$26,010
Amgen(2 entities)	72	$14,622
Amryt Pharma Holdings Ltd	10	$4,206
Antares Pharma, Inc.	11	$4,143
Recordati_rare_diseases_inc.	14	$2,890
Novo Nordisk	86	$1,772
Lilly USA, LLC	53	$1,121
Mannkind Corporation	35	$826
Radius Health, Inc.	25	$704
IBSA Pharma Inc.	24	$495
AbbVie	18	$452
Abbott	19	$449
AstraZeneca(2 entities)	19	$430
Boehringer Ingelheim	14	$390
Bayer	15	$328
Xeris Pharmaceuticals, Inc.	11	$222
Sanofi-aventis U.S. LLC	10	$214
Pfizer	8	$188
Zealand Pharma US, Inc.	7	$151
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$137
Arbor Pharmaceuticals, Inc.	6	$101
Dexcom, Inc.	4	$94
Amarin Pharma, Inc.	4	$93
Tolmar, Inc.	6	$92
Eisai Inc.	5	$90
BD	2	$79
Merck	4	$66
Neurocrine Biosciences, Inc.	2	$65
Clarus Therapeutics Inc.	3	$63
Vivus LLC	3	$59
Alfasigma USA, Inc.	1	$58
Acella Pharmaceuticals, LLC	3	$56
Novartis	2	$55
Sumitomo Pharma America, Inc.	2	$54
Verity Pharmaceuticals Inc.	2	$53
Kyowa Kirin, Inc.	2	$52
Strongbridge US Inc.	2	$49
Johnson & Johnson Vision Care, Inc.	3	$47
Ipsen Biopharmaceuticals, Inc	2	$47
Johnson & Johnson	2	$46
Vertical Pharmaceuticals, LLC	2	$35
Insulet Corporation	2	$35
Currax Pharmaceuticals LLC	2	$34
Amneal Pharmaceuticals LLC	2	$31
Phathom Pharmaceuticals, Inc.	1	$29
Acerus Pharmaceuticals Corporation	1	$28
Biomarin Pharmaceutical Inc.	1	$27
Shire North American Group Inc	1	$25
EUSA Pharma (US) LLC	1	$23
Chiesi USA, Inc.	1	$20
Takeda Pharmaceuticals U.S.A., Inc.	1	$20
Avion Pharmaceuticals	1	$19
Endo Pharmaceuticals Inc.	1	$18
BETA Bionics, Inc.	1	$18
Oyster Point Pharma, Inc.	1	$16
Azurity Pharmaceuticals, Inc.	1	$14
Ascend Therapeutics US, LLC	1	$12

How this compares

$2,156,041 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Medicare billing

Part B allowed, 2024

$192,577

Medicare patients

207

Services billed

5,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Beverly Hills

Anne PetersBeverly Hills$560K
Jerrold OlefskySan Diego$26.5M
Mark ChristiansenWalnut Creek$22.9M
Timothy BaileyEscondido$22.3M
Stanley HsiaLos Angeles$19.8M
Juan FriasSan Diego$14.1M
Paul NorwoodFresno$6.2M
Athena Philis-Tsimikasla Jolla$6M
David AhnNewport Beach$5.8M
Shlomo MelmedLos Angeles$3.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →